Qiagen, Clinical Genomics team up on colorectal cancer liquid biopsy

Blood
Qiagen has added its ccfDNA blood-collection tubes to Clinical Genomics' liquid biopsy for colorectal cancer recurrence.

Diagnostics giant Qiagen has integrated its circulating cell-free DNA (ccfDNA) blood-collection tubes in Clinical Genomics’ liquid biopsy test for the recurrence of colorectal cancer.

Clinical Genomics’ Colvera blood test is designed to detect the recurrence of colorectal cancer by spotting fragments of DNA that escape from a tumor into the bloodstream. The liquid biopsy may be able to catch colorectal cancer recurrence earlier than other tests, the company says.

The PCR-based assay has been shown to detect more than twice the number of colorectal cancer recurrence cases than the currently recommended blood test, Clinical Genomics said in a statement.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Clinical Genomics brings home $15M for two-gene colorectal cancer test

The PAXgene Blood ccfDNA tube was developed by PreAnalytiX, a joint venture between Qiagen and Becton Dickinson. The PAXgene system allows whole blood samples to be stored for up to seven days before they are processed and tested. Samples for the Colavera test will be shipped to Clinical Genomics' lab in Bridgewater, New Jersey.

“The Colvera test represents a unique opportunity for convenient, noninvasive monitoring of colorectal cancer patients by detecting methylated circulating tumor DNA that may indicate recurrence of a cancer,” said Thierry Bernard, molecular diagnostics chief and a senior vice president at Qiagen, in the statement.

RELATED: 'Capsule colonoscope' could pave the way for more colorectal cancer screenings

“We are excited to roll out the PAXgene System as the front-end solution to allow physicians to provide Colvera testing to CRC patients as conveniently as possible,” said Clinical Genomics CEO Lawrence LaPointe, Ph.D., in the statement. “PAXgene allows a simple blood collection at the physician’s office, with no on-site processing required, which is a great step forward from our alternative sample collection methods.”

Suggested Articles

Following an FBI raid and the replacement of its leadership, it’s come to light that the data behind uBiome’s microbiome test may contain flaws.

The National Institutes of Health has tapped the genomics firm Color to help participants understand and act on their results.

In a $72 million deal, Inex Innovations Exchange and Nova Satra will combine their laboratory, R&D and distribution arms.